We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisory Committee Supports Mesoblast’s Stem Cell Treatment Ryoncil
FDA Advisory Committee Supports Mesoblast’s Stem Cell Treatment Ryoncil
The FDA’s Oncologic Drugs Advisory Committee voted 8-2 yesterday in support of Mesoblast’s stem-cell treatment Ryoncil (remestemcel-L) for steroid-refractory acute graft versus host disease in children.